Lineage Cell Therapeutics, Inc. (LCTX) stock
LCTXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/3048% above fair value
$0.91−0.08 (-7.64%)
Close on Nov 13, 2026Market cap $231.31MP/E –Yield –
Lineage Cell Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Lineage Cell Therapeutics's total assets was $100.11M at Sep 30, 2026. For fiscal 2025 it was $112.58M, down 0.6% from the year before. Over ten years it grew 1.7% a year on average. The highest annual figure on record is $174.55M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $112.58M | -0.6% |
| FY2024 | Dec 31, 2024 | $113.22M | +12.1% |
| FY2023 | Dec 31, 2023 | $101.02M | -18.3% |
| FY2022 | Dec 31, 2022 | $123.66M | -29.2% |
| FY2021 | Dec 31, 2021 | $174.55M | +61.7% |
| FY2020 | Dec 31, 2020 | $107.95M | -14.0% |
| FY2019 | Dec 31, 2019 | $125.48M | +23.4% |
| FY2018 | Dec 31, 2018 | $101.66M | -41.3% |
| FY2017 | Dec 31, 2017 | $173.24M | +21.5% |
| FY2016 | Dec 31, 2016 | $142.57M | +50.6% |
| FY2015 | Dec 31, 2015 | $94.66M | +26.4% |
| FY2014 | Dec 31, 2014 | $74.90M | +29.7% |
| FY2013 | Dec 31, 2013 | $57.73M | +94.1% |
| FY2012 | Dec 31, 2012 | $29.75M | -35.1% |
| FY2011 | Dec 31, 2011 | $45.83M | -14.0% |
| FY2010 | Dec 31, 2010 | $53.27M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $100.11M | +11.7% |
| Q2 FY2026 | Jun 30, 2026 | $106.22M | +17.0% |
| Q1 FY2026 | Mar 31, 2026 | $109.53M | -2.0% |
| Q4 FY2025 | Dec 31, 2025 | $112.58M | -0.6% |
| Q3 FY2025 | Sep 30, 2025 | $89.64M | -7.2% |
| Q2 FY2025 | Jun 30, 2025 | $90.80M | -11.7% |
| Q1 FY2025 | Mar 31, 2025 | $111.75M | +3.0% |
| Q4 FY2024 | Dec 31, 2024 | $113.22M | +12.1% |
| Q3 FY2024 | Sep 30, 2024 | $96.59M | -9.0% |
| Q2 FY2024 | Jun 30, 2024 | $102.80M | -8.0% |
| Q1 FY2024 | Mar 31, 2024 | $108.48M | -4.2% |
| Q4 FY2023 | Dec 31, 2023 | $101.02M | -18.3% |
| Q3 FY2023 | Sep 30, 2023 | $106.15M | -19.1% |
| Q2 FY2023 | Jun 30, 2023 | $111.69M | -17.8% |
| Q1 FY2023 | Mar 31, 2023 | $113.21M | -21.7% |
| Q4 FY2022 | Dec 31, 2022 | $123.66M | -29.2% |
| Q3 FY2022 | Sep 30, 2022 | $131.15M | -0.0% |
| Q2 FY2022 | Jun 30, 2022 | $135.92M | +0.9% |
| Q1 FY2022 | Mar 31, 2022 | $144.52M | +13.0% |
| Q4 FY2021 | Dec 31, 2021 | $174.55M | +61.7% |
| Q3 FY2021 | Sep 30, 2021 | $131.21M | +27.3% |
| Q2 FY2021 | Jun 30, 2021 | $134.75M | +20.2% |
| Q1 FY2021 | Mar 31, 2021 | $127.93M | +7.6% |
| Q4 FY2020 | Dec 31, 2020 | $107.95M | -14.0% |
| Q3 FY2020 | Sep 30, 2020 | $103.09M | -22.5% |
| Q2 FY2020 | Jun 30, 2020 | $112.08M | -26.1% |
| Q1 FY2020 | Mar 31, 2020 | $118.88M | -35.3% |
| Q4 FY2019 | Dec 31, 2019 | $125.48M | +23.4% |
| Q3 FY2019 | Sep 30, 2019 | $132.98M | -24.5% |
| Q2 FY2019 | Jun 30, 2019 | $151.69M | +35.1% |
| Q1 FY2019 | Mar 31, 2019 | $183.72M | +66.4% |
| Q4 FY2018 | Dec 31, 2018 | $101.66M | -41.3% |
| Q3 FY2018 | Sep 30, 2018 | $176.08M | -20.6% |
| Q2 FY2018 | Jun 30, 2018 | $112.25M | -41.9% |
| Q1 FY2018 | Mar 31, 2018 | $110.40M | -46.2% |
| Q4 FY2017 | Dec 31, 2017 | $173.24M | +21.5% |
| Q3 FY2017 | Sep 30, 2017 | $221.87M | – |
| Q2 FY2017 | Jun 30, 2017 | $193.35M | – |
| Q1 FY2017 | Mar 31, 2017 | $205.22M | – |
| Q4 FY2016 | Dec 31, 2016 | $142.57M | – |
See a number that looks wrong?